SCHEMBL4863904

SCHEMBL4863904

CCn1c(-c2cnn(C)c2)c([N+](=O)[O-])c(=O)n(CC)c1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
MAPT P10636 2/20 0.37
HTT P42858 2/20 0.37
NPC1 O15118 1/20 0.37
MITF O75030 1/20 0.37
LMNA P02545 1/20 0.37
AGTR1 P30556 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
TLR9 Q9NR96 1/20 0.37
ERN1 O75460 1/20 0.37
CYP1A2 P05177 1/20 0.35
BRD4 O60885 1/20 0.35
PARG Q86W56 4/20 0.34
KMT2A Q03164 2/20 0.34
BAZ2B Q9UIF8 1/20 0.34
BAZ2A Q9UIF9 1/20 0.34
CFTR P13569 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4864869 0.94 ADORA2B (0.36) ALDH1A1MAPTHTTNPC1MITF
SCHEMBL4865970 0.88 ADORA2B (0.40) ALDH1A1MAPTLMNAPARGADORA2A
SCHEMBL4867667 0.86 ADORA2A (0.37) ALDH1A1LMNANPSR1ERN1PARG
SCHEMBL4860816 0.85 PARG (0.38) NPSR1ERN1BRD4PARGBAZ2B
SCHEMBL4863596 0.84 ADORA2A (0.38) ALDH1A1MAPTHTTNPC1MITF
SCHEMBL4866998 0.83 PARG (0.38) ALDH1A1HTTERN1CYP1A2BRD4
SCHEMBL4865956 0.82 RGS4 (0.38) LMNANPSR1ERN1PARGKMT2A
SCHEMBL4865967 0.82 ADORA2B (0.42) ERN1PARGADORA2APDE4APDE4B
SCHEMBL4866480 0.81 PARG (0.42) HTTPARGKMT2ABAZ2BBAZ2A
SCHEMBL4863501 0.81 HSP90AA1 (0.46) ALDH1A1MAPTHTTNPC1MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449473-B2 Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
EP-1678181-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-07-12 EP disclosed
US-20050119287-A1 A2B adenosine receptor antagonists GILEAD PALO ALTO, INC. 2005-06-02 US disclosed
WO-2005042534-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119287-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA3 ALDH1A1 1178/4885MAPT 4503/4885HTT 2328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.